5/28/2013

Most drug candidates that fail to make it to market passed safety tests but did not work for their intended target, according to a paper published in Science Translational Medicine. Abandoned compounds could be a rich source of future drugs, but only if someone can figure out how to make money off of them. Extending patent exclusivity for repurposed drugs could help, authors Steven Paul and Freda Lewis-Hall say.

Related Summaries